Lyka Labs Ltd

₹ 58.3 1.23%

29 May - close price

About

Incorporated in 1976, Lyka Labs Ltd is in the development, manufacture and marketing of quality finished dosages^[1]

Key Points

Business Overview:^[1]
LLL is a WHO-GMP certified and ISO 9001- certified manufacturer of Pharmaceutical Formulations & Active Pharmaceutical Ingredients across various therapeutic segments, including Lyophilized injections, topical formulations of cream, ointment, foams, gels & lotions.

Website BSE NSE

Market Cap ₹ 208 Cr.
Current Price ₹ 58.3
High / Low ₹ 126 / 44.1
Stock P/E
Book Value ₹ 25.9
Dividend Yield 0.00 %
ROCE -6.10 %
ROE -10.2 %
Face Value ₹ 10.0

Add ratio to table

Edit ratios

Pros

Company's working capital requirements have reduced from 32.2 days to 22.8 days

Cons

Company has low interest coverage ratio.
The company has delivered a poor sales growth of 8.29% over past five years.
Company has a low return on equity of -2.04% over last 3 years.
Company might be capitalizing the interest cost

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	22.24	22.88	27.99	32.56	27.77	30.11	41.16	33.80	33.43	33.03	36.66	30.73	28.03
	18.94	20.24	23.82	25.69	25.75	26.40	36.21	28.61	29.35	29.35	39.20	29.08	34.48
Operating Profit	3.30	2.64	4.17	6.87	2.02	3.71	4.95	5.19	4.08	3.68	-2.54	1.65	-6.45
OPM %	14.84%	11.54%	14.90%	21.10%	7.27%	12.32%	12.03%	15.36%	12.20%	11.14%	-6.93%	5.37%	-23.01%
	0.02	0.38	-0.18	0.54	0.32	0.56	0.03	0.83	0.82	0.63	1.09	1.16	0.61
Interest	2.85	1.35	1.19	1.28	1.07	0.65	0.54	0.61	0.47	0.85	0.79	0.82	0.70
Depreciation	3.47	3.47	3.59	2.84	2.90	1.76	1.76	1.83	1.42	2.11	2.15	2.15	2.04
Profit before tax	-3.00	-1.80	-0.79	3.29	-1.63	1.86	2.68	3.58	3.01	1.35	-4.39	-0.16	-8.58
Tax %	0.00%	7.22%	-22.78%	38.60%	28.22%	30.65%	28.36%	24.30%	32.89%	26.67%	-26.65%	-6.25%	-6.06%
	-3.01	-1.85	-0.49	1.78	-2.09	1.29	1.91	2.70	2.03	0.99	-3.22	-0.15	-8.07
EPS in Rs	-0.98	-0.56	-0.15	0.54	-0.63	0.40	0.59	0.76	0.50	0.26	-0.94	0.00	-2.13
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

	Jun 2015	Mar 2016 9m	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	166	130	110	60	71	61	86	194	93	111	138	128
	139	110	87	63	73	65	67	93	76	95	121	132
Operating Profit	28	20	23	-4	-2	-4	20	101	17	16	18	-4
OPM %	17%	16%	21%	-6%	-3%	-6%	23%	52%	18%	14%	13%	-3%
	4	8	-2	4	1	-30	0	-4	-4	1	2	4
Interest	24	15	19	10	7	20	26	20	12	5	2	3
Depreciation	11	9	10	11	7	8	8	17	14	13	7	8
Profit before tax	-3	4	-8	-20	-15	-62	-14	59	-13	-1	11	-12
Tax %	31%	-5%	-19%	-5%	-59%	1%	-29%	35%	-0%	182%	29%	-11%
	-5	4	-7	-19	-6	-63	-10	38	-13	-3	8	-10
EPS in Rs	-2.29	1.67	-2.51	-6.14	-1.97	-21.10	-4.03	13.59	-4.30	-0.75	2.24	-2.81
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Compounded Sales Growth
10 Years:	0%
5 Years:	8%
3 Years:	11%
TTM:	-7%

Compounded Profit Growth
10 Years:	%
5 Years:	1%
3 Years:	-32%
TTM:	-226%

Stock Price CAGR
10 Years:	-2%
5 Years:	-4%
3 Years:	-15%
1 Year:	-53%

Return on Equity
10 Years:	%
5 Years:	%
3 Years:	-2%
Last Year:	-10%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

	Jun 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	22	22	22	28	28	29	29	29	31	33	36	36
Reserves	20	22	16	21	15	-43	-54	-15	15	35	68	57
	137	121	126	113	96	141	163	130	75	59	39	49
	100	77	88	67	76	73	52	42	31	30	33	33
Total Liabilities	279	242	252	229	216	200	190	186	152	157	176	175
	122	104	133	116	108	105	98	94	68	58	85	87
CWIP	27	30	24	28	31	28	26	18	16	23	1	2
Investments	0	0	0	0	0	0	0	0	0	0	0	0
	130	107	94	85	77	68	66	74	67	76	90	86
Total Assets	279	242	252	229	216	200	190	186	152	157	176	175

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

	Jun 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	27	12	31	11	27	5	9	79	9	2	2	5
	37	17	-13	-3	-4	-0	-0	-6	7	-9	-12	-9
	-60	-30	-19	-10	-23	3	-12	-63	-22	2	5	4
Net Cash Flow	4	-1	-0	-3	-1	9	-3	10	-5	-6	-5	0
Free Cash Flow	55	28	18	7	23	4	8	72	15	-7	-10	-6
CFO/OP	97%	60%	143%	-318%	-1,462%	-131%	49%	79%	52%	21%	28%	-152%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

	Jun 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	124	121	97	125	75	48	37	35	79	89	114	100
Inventory Days	77	56	90	139	65	69	41	56	68	78	82	99
Days Payable	220	218	266	301	216	192	141	96	91	98	98	122
Cash Conversion Cycle	-18	-41	-79	-37	-75	-76	-63	-5	55	68	97	77
Working Capital Days	-220	-242	-357	-735	-265	-242	-118	-121	-0	23	51	23
ROCE %	10%	7%	9%	-8%	-5%	-6%	10%	61%	5%	4%	10%	-6%

Insights

In beta

Jun 2015

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Number of Permanent Employees
count ・Standalone data

xxx	xxx	xxx	xxx	xxx	xx	xxx	xxx		xxx
xx.xx	xx.xx	xx.xx	x.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx		x.xx
	xx.xx	xx.xx	xx.xx	xx.xx	xxx.xx	xxx.xx	xxx.xx
xxx	xx		xxx		xx		xx		xx
xx	xx		x		xx		x		xx
					xx	xx	xx		xx
						x	xx	xxx
xx			xxx
xxx			xxx

Please log in to see hidden values.

R&D Expenditure Capitalized as Assets (Self-Generated)
INR Lakhs ・Standalone data

Electricity Consumption per Million Pack Formulation
'000 kwh ・Standalone data

Expected/Pending Product Registrations
count

New Product Registrations Received
count

Lyophilization Manufacturing Capacity Enhancement (Incremental)
% increase ・Standalone data

Animal Healthcare Division Revenue Contribution
INR Million

Patents Filed (Cumulative)
count ・Standalone data

Total Product Registrations In Force
count

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	54.58%	54.81%	54.81%	54.81%	58.11%	58.11%	58.11%	58.16%	58.16%	58.16%	58.16%	58.16%
	0.17%	0.18%	0.17%	0.17%	0.15%	0.15%	0.15%	0.24%	0.16%	0.17%	0.17%	0.29%
	0.41%	0.41%	0.62%	0.81%	0.75%	0.66%	0.66%	0.66%	0.66%	0.66%	0.66%	0.66%
	44.84%	44.61%	44.41%	44.21%	40.99%	41.08%	41.07%	40.93%	41.02%	40.99%	40.99%	40.89%
No. of Shareholders	27,202	26,652	26,422	25,717	25,716	28,943	29,099	28,472	28,189	27,743	27,155	26,727

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	23.99%	18.66%	18.13%	19.88%	19.88%	47.79%	51.00%	54.81%	58.16%	58.16%
	4.74%	3.57%	3.64%	3.50%	3.50%	1.12%	0.18%	0.17%	0.24%	0.29%
	1.70%	1.01%	1.01%	0.66%	0.47%	1.19%	3.74%	0.81%	0.66%	0.66%
	69.57%	76.75%	77.22%	75.96%	76.15%	49.89%	45.08%	44.21%	40.93%	40.89%
No. of Shareholders	19,769	20,791	20,281	19,642	19,350	26,220	26,820	25,717	28,472	26,727

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Lyka Labs Ltd

Lyka Labs Ltd

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Insights

Shareholding Pattern

Documents

Announcements

Annual reports

Credit ratings